Other clinically investigated approaches include pro-inflammatory macrophages modified with a cytokine cocktail to downregulate and stimulate cancer cell phagocytosis (SIRPant-M) [186] and an intraperitoneally injected autologous monocyte and IFN infusion [187]. This evidence concerns the gene IFNA1 and cancer.